GlassScriptPhysician profile
Edwin O Molina
NPI 1588014161
$40,442.79
in general payments reported to CMS, 2019-2025
17 companies · $13K in 2025
The $13K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,065 · 2022: $2,270 · 2023: $22K · 2024: $905 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $3,491 · Travel and Lodging: $2,871 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $19,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,585.00 |
| Food and Beverage | $3,491.43 |
| Travel and Lodging | $2,871.07 |
| Education | $160.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20,190.88 | 2021-2025 | Ensite, Aveir, Cardiomems |
| Pfizer INC. | $8,750.34 | 2025 | |
| Merck Sharp & Dohme LLC | $3,339.13 | 2021-2025 | Winrevair, Pneumovax 23, Verquvo |
| Boston Scientific Corporation | $2,868.63 | 2021-2025 | Resonate El Icd Vr, Emblem Mri S-Icd, Watchman Access System |
| Abiomed | $1,807.07 | 2023 | Impella |
| Medtronic, INC. | $864.99 | 2021-2025 | Corevalve Evolut R, Endurant Iis, Micra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $571.24 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $469.97 | 2021-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $426.47 | 2021-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $321.69 | 2021-2025 | Camzyos, Eliquis |
| Pbg Puerto Rico LLC | $280.90 | 2021-2025 | |
| Amgen INC. | $267.40 | 2022-2025 | Repatha |
| Scpharmaceuticals INC. | $125.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $87.74 | 2021-2022 | |
| United Therapeutics Corporation | $24.96 | 2025 | Tyvaso |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23.95 | 2025 | Wainua |
| Bayer Puerto Rico INC. | $22.43 | 2025 | Kerendia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Molina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.